Literature DB >> 3501426

Postantibiotic effect of roxithromycin, erythromycin, and clindamycin against selected gram-positive bacteria and Haemophilus influenzae.

B Kuenzi1, C Segessenmann, A U Gerber.   

Abstract

Recent experimental work has shown that a so-called PAE (postantibiotic effect, i.e. persistent suppression of regrowth after short exposure of bacteria to the study drug in vitro) is a feature of most current antibiotics. However, marked quantitative differences were found between different types of antibiotics and also between Gram-positive and Gram-negative organisms studied. A PAE has not yet been demonstrated for roxithromycin, a new macrolide antibiotic. Therefore, we compared the PAE of roxithromycin, erythromycin, and clindamycin against laboratory strains and clinical isolates of Staphylococcus aureus, Streptococcus pyogenes, Str. pneumoniae, and Haemophilus influenzae in vitro. Identical multiples of the MIC and identical exposure times resulted in similar PAEs for the three study drugs tested. Good correlations could be found between the area under the in-vitro concentration-vs-time curve (AUC) and PAEs. The longest PAE of 9.6 h was observed after exposure of Str. pneumoniae to 1.9 mg/l of roxithromycin for 6 h.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501426     DOI: 10.1093/jac/20.suppl_b.39

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004.

Authors:  W J Munckhof; G Borlace; J D Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Comparative study of bactericidal activities, postantibiotic effects, and effects of bacterial virulence of penicillin G and six macrolides against Streptococcus pneumoniae.

Authors:  K Fuursted; J D Knudsen; M B Petersen; R L Poulsen; D Rehm
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

3.  The postantibiotic effect of imipenem: relationship with drug concentration, duration of exposure, and MIC.

Authors:  W J Munckhof; D Olden; J D Turnidge
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth.

Authors:  J A Karlowsky; G G Zhanel; R J Davidson; S R Zieroth; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells.

Authors:  W S Champney; C L Tober
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans.

Authors:  A Buxbaum; A Georgopoulos
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

Review 7.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

8.  Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 9.  Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides.

Authors:  G G Zhanel; W A Craig
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

10.  Ante-partum necrotising myometritis due to Streptococcal toxic shock.

Authors:  Sanjay Tarvade; Andrew S Lane
Journal:  J Intensive Care Soc       Date:  2015-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.